Assessing new technology: what is best for the patient, the surgeon, and the healthcare system
In this issue of Fertility and Sterility, Sandberg et al (1). present a very thorough meta-analysis on the short- and long-term quality of life outcomes and reintervention rates of surgical and non-surgical technologies and techniques for the uterine sparing treatment of fibroid-related symptoms. They have included available data on surgical abdominal and hysteroscopic myomectomy as well as each Food and Drug Administration approved devices including uterine artery embolization, magnetic resonance imaging-guided HIFU, and laparoscopic and hysteroscopic radiofrequency ablation that utilize ultrasound guidance (2-5).
Source: fertstert.org
Assessing new technology: what is best for the patient, the surgeon, and the healthcare system
More from Embryology and Reproductive MedicineMore posts in Embryology and Reproductive Medicine »
- Life after Stillbirth
- The possible impact of COVID 19 on fertility and ART
- Human embryonic stem cell–derived blastocyst-like spheroids resemble human trophectoderm during early implantation process
- What support is available for you in hospital if you lose your baby
- Estrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis
Be First to Comment